Sec Form 13G Filing - VENROCK ASSOCIATES V LP filing for CONSTELLATION PHARMACEUTICALS INC (CNST) - 2020-02-14

 

 

	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549

 

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

Constellation Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

210373106

(CUSIP Number)

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o	Rule 13d-1(b)
x	Rule 13d-1(c)
o	Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Associates V, L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 1,740,945(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 1,740,945(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,740,945(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 4.2%(4)
	12.	Type of Reporting Person (See Instructions) PN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 4,016,873 shares of common stock held by the VHCP Entities. The Venrock V Entities disclaim beneficial ownership over the shares held by the VHCP Entities.
(4)	This percentage is calculated based upon (i) 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019, plus (ii) an aggregate of 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Partners V, L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 1,740,945(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 1,740,945(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,740,945(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 4.2%(4)
	12.	Type of Reporting Person (See Instructions) PN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 4,016,873 shares of common stock held by the VHCP Entities. The Venrock V Entities disclaim beneficial ownership over the shares held by the VHCP Entities.
(4)	This percentage is calculated based upon (i) 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019, plus (ii) an aggregate of 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Entrepreneurs Fund V, L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 1,740,945(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 1,740,945(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,740,945(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 4.2%(4)
	12.	Type of Reporting Person (See Instructions) PN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 4,016,873 shares of common stock held by the VHCP Entities. The Venrock V Entities disclaim beneficial ownership over the shares held by the VHCP Entities.
(4)	This percentage is calculated based upon (i) 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019, plus (ii) an aggregate of 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Management V, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 1,740,945(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 1,740,945(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,740,945(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 4.2%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 4,016,873 shares of common stock held by the VHCP Entities. The Venrock V Entities disclaim beneficial ownership over the shares held by the VHCP Entities.
(4)	This percentage is calculated based upon (i) 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019, plus (ii) an aggregate of 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Partners Management V, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 1,740,945(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 1,740,945(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,740,945(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 4.2%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 4,016,873 shares of common stock held by the VHCP Entities. The Venrock V Entities disclaim beneficial ownership over the shares held by the VHCP Entities.
(4)	This percentage is calculated based upon (i) 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019, plus (ii) an aggregate of 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons VEF Management V, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 1,740,945(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 1,740,945(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,740,945(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 4.2%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 4,016,873 shares of common stock held by the VHCP Entities. The Venrock V Entities disclaim beneficial ownership over the shares held by the VHCP Entities.
(4)	This percentage is calculated based upon (i) 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019, plus (ii) an aggregate of 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Healthcare Capital Partners II, L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) PN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons VHCP Co-Investment Holdings II, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Benefic ially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons VHCP Management II, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Venrock Healthcare Capital Partners III, L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) PN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons VHCP Co-Investment Holdings III, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons VHCP Management III, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) OO

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management II I, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Koh, Bong
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) IN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106
	1.	Name of Reporting Persons Shah, Nimish
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x(1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With:			5.		Sole Voting Power 0
			6.		Shared Voting Power 4,016,873(2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 4,016,873(2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,016,873(2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) x(3)
	11.	Percent of Class Represented by Amount in Row (9) 9.7%(4)
	12.	Type of Reporting Person (See Instructions) IN

 

(1)	This Schedule 13G/A is being filed by (i) Venrock Associates V, L.P. (“VA-V”), Venrock Partners V, L.P. (“VP-V”), Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), Venrock Management V, LLC, the general partner of VA V (“VM-V”), Venrock Partners Management V, LLC, the general partner of VP V (“VPM-V”), and VEF Management V, LLC, the general partner of VEF V (“VEFM-V” and together with VA-V, VP-V, VEF-V, VM-V and VPM-V, the “Venrock V Entities”) and (ii) Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), VHCP Management II, LLC, the general partner of VHCP-II and the manager of VHCP-II Co-Invest (“VHCPM-II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest (“VHCPM-III”), Bong Koh (“Koh”) and Nimish Shah (“Shah”, and together with VHCP-II, VHCP-II Co-Invest, VHCPM-II, VHCP-III, VHCP-III Co-Invest, VHCPM-III and Koh, the “VHCP Entities”). The Venrock V Entities and the VHCP Entities are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G/A.
(2)	Consists of (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.
(3)	The shares included on rows 6, 8 and 9 do not include an aggregate of 1,725,892 shares of common stock and 15,053 shares of common stock underlying immediately exercisable warrants held by the Venrock V Entities. The VHCP Entities disclaim beneficial ownership over the shares held by the Venrock V Entities.
(4)	This percentage is calculated based upon 41,600,142 shares of common stock outstanding as of December 13, 2019, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 17, 2019.

 

 

CUSIP No. 210373106

 

Introductory Note: This Statement on Schedule 13G/A is filed on behalf of the following entities in respect of the common stock of Constellation Pharmaceuticals, Inc.:

 

· Venrock Associates V, L.P. (“VA-V”), a limited partnership organized under the laws of the State of Delaware;

· Venrock Partners V, L.P. (“VP-V”), a limited partnership organized under the laws of the State of Delaware;

· Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), a limited partnership organized under the laws of the State of Delaware;

· Venrock Management V, LLC (“VM-V”), a limited liability company organized under the laws of the State of Delaware;

· Venrock Partners Management V, LLC (“VPM-V”), a limited liability company organized under the laws of the State of Delaware;

· VEF Management V, LLC (“VEFM-V”), a limited liability company organized under the laws of the State of Delaware;

· Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), a limited partnership organized under the laws of the State of Delaware;

· VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), a limited liability company organized under the laws of the State of Delaware;

· VHCP Management II, LLC (“VHCPM-II”), a limited liability company organized under the laws of the State of Delaware;

· Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), a limited partnership organized under the laws of the State of Delaware;

· VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), a limited liability company organized under the laws of the State of Delaware;

· VHCP Management III, LLC (“VHCPM-III”), a limited liability company organized under the laws of the State of Delaware;

· Bong Koh, a United States citizen; and

· Nimish Shah, a United States citizen.

 

Item 1.

 

(a) Name of Issuer

 

Constellation Pharmaceuticals, Inc.

 

(b) Address of Issuer’s Principal Executive Offices

 

215 First Street, Suite 200

Cambridge, Massachusetts 02142

 

Item 2.

 

(a) Name of Person Filing

 

Venrock Associates V, L.P.

Venrock Partners V, L.P.

Venrock Entrepreneurs Fund V, L.P.

Venrock Management V, LLC

Venrock Partners Management V, LLC

VEF Management V, LLC

Venrock Healthcare Capital Partners II, L.P.

VHCP Co-Investment Holdings II, LLC

VHCP Management II, LLC

Venrock Healthcare Capital Partners III, L.P.

VHCP Co-Investment Holdings III, LLC

VHCP Management III, LLC

Bong Koh

Nimish Shah

 

 

CUSIP No. 210373106

 

(b) Address of Principal Business Office or, if none, Residence

 

New York Office:		Palo Alto Office:
7 Bryant Park		3340 Hillview Avenue
23rd Floor		Palo Alto, CA 94304
New York, NY 10018

 

(c) Citizenship

 

Each of VA-V, VP-V, VEF-V, VHCP-II and VHCP-III are limited partnerships organized in the State of Delaware. Each of VM-V, VPM-V, VEFM-V, VHCP-II Co-Invest, VHCPM-II, VHCP-III Co-Invest and VHCPM-III are limited liability companies organized in the State of Delaware. Both Koh and Shah are United States citizens.

 

(d) Title of Class of Securities

 

Common Stock

 

(e) CUSIP Number

 

210373106

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable

 

Item 4. Ownership

 

(a) Amount Beneficially Owned as of December 31, 2019:

 

Venrock Associates V, L.P.		1,740,945	(1)
Venrock Partners V, L.P.		1,740,945	(1)
Venrock Entrepreneurs Fund V, L.P.		1,740,945	(1)
Venrock Management V, LLC		1,740,945	(1)
Venrock Partners Management V, LLC		1,740,945	(1)
VEF Management V, LLC		1,740,945	(1)
Venrock Healthcare Capital Partners II, L.P.		4,016,873	(2)
VHCP Co-Investment Holdings II, LLC		4,016,873	(2)
VHCP Management II, LLC		4,016,873	(2)
Venrock Healthcare Capital Partners III, L.P.		4,016,873	(2)
VHCP Co-Investment Holdings III, LLC		4,016,873	(2)
VHCP Management III, LLC		4,016,873	(2)
Bong Koh		4,016,873	(2)
Nimish Shah		4,016,873	(2)

 

(b) Percent of Class as of December 31, 2019:

 

Venrock Associates V, L.P.		4.2	%
Venrock Partners V, L.P.		4.2	%
Venrock Entrepreneurs Fund V, L.P.		4.2	%
Venrock Management V, LLC		4.2	%
Venrock Partners Management V, LLC		4.2	%
VEF Management V, LLC		4.2	%
Venrock Healthcare Capital Partners II, L.P.		9.7	%
VHCP Co-Investment Holdings II, LLC		9.7	%
VHCP Management II, LLC		9.7	%
Venrock Healthcare Capital Partners III, L.P.		9.7	%
VHCP Co-Investment Holdings III, LLC		9.7	%
VHCP Management III, LLC		9.7	%
Bong Koh		9.7	%
Nimish Shah		9.7	%

 

 

CUSIP No. 210373106

 

(c) Number of shares as to which the person has, as of December 31, 2019:

 

(i) Sole power to vote or to direct the vote

 

Venrock Associates V, L.P.		0
Venrock Partners V, L.P.		0
Venrock Entrepreneurs Fund V, L.P.		0
Venrock Management V, LLC		0
Venrock Partners Management V, LLC		0
VEF Management V, LLC		0
Venrock Healthcare Capital Partners II, L.P.		0
VHCP Co-Investment Holdings II, LLC		0
VHCP Management II, LLC		0
Venrock Healthcare Capital Partners III, L.P.		0
VHCP Co-Investment Holdings III, LLC		0
VHCP Management III, LLC		0
Bong Koh		0
Nimish Shah		0

 

(ii) Shared power to vote or to direct the vote

 

Venrock Associates V, L.P.		1,740,945	(1)
Venrock Partners V, L.P.		1,740,945	(1)
Venrock Entrepreneurs Fund V, L.P.		1,740,945	(1)
Venrock Management V, LLC		1,740,945	(1)
Venrock Partners Management V, LLC		1,740,945	(1)
VEF Management V, LLC		1,740,945	(1)
Venrock Healthcare Capital Partners II, L.P.		4,016,873	(2)
VHCP Co-Investment Holdings II, LLC		4,016,873	(2)
VHCP Management II, LLC		4,016,873	(2)
Venrock Healthcare Capital Partners III, L.P.		4,016,873	(2)
VHCP Co-Investment Holdings III, LLC		4,016,873	(2)
VHCP Management III, LLC		4,016,873	(2)
Bong Koh		4,016,873	(2)
Nimish Shah		4,016,873	(2)

 

(iii) Sole power to dispose or to direct the disposition of

 

Venrock Associates V, L.P.		0
Venrock Partners V, L.P.		0
Venrock Entrepreneurs Fund V, L.P.		0
Venrock Management V, LLC		0
Venrock Partners Management V, LLC		0
VEF Management V, LLC		0
Venrock Healthcare Capital Partners II, L.P.		0
VHCP Co-Investment Holdings II, LLC		0
VHCP Management II, LLC		0
Venrock Healthcare Capital Partners III, L.P.		0
VHCP Co-Investment Holdings III, LLC		0
VHCP Management III, LLC		0
Bong Koh		0
Nimish Shah		0

 

(iv) Shared power to dispose or to direct the disposition of

 

Venrock Associates V, L.P.		1,740,945	(1)
Venrock Partners V, L.P.		1,740,945	(1)
Venrock Entrepreneurs Fund V, L.P.		1,740,945	(1)
Venrock Management V, LLC		1,740,945	(1)
Venrock Partners Management V, LLC		1,740,945	(1)
VEF Management V, LLC		1,740,945	(1)
Venrock Healthcare Capital Partners II, L.P.		4,016,873	(2)
VHCP Co-Investment Holdings II, LLC		4,016,873	(2)
VHCP Management II, LLC		4,016,873	(2)
Venrock Healthcare Capital Partners III, L.P.		4,016,873	(2)
VHCP Co-Investment Holdings III, LLC		4,016,873	(2)
VHCP Management III, LLC		4,016,873	(2)
Bong Koh		4,016,873	(2)
Nimish Shah		4,016,873	(2)

 

 

CUSIP No. 210373106

 

(1)	These shares are owned directly as follows: (i) 1,557,276 shares of common stock and 13,583 shares of common stock underlying immediately exercisable warrants held by VA-V, (ii) 132,026 shares of common stock and 1,151 shares of common stock underlying immediately exercisable warrants held by VP-V and (iii) 36,590 shares of common stock and 319 shares of common stock underlying immediately exercisable warrants held by VEF-V.
(2)	These shares are owned directly as follows: (i) 1,067,801 shares of common stock held by VHCP-II, (ii) 432,830 shares of common stock held by VHCP-II Co-Invest, (iii) 2,287,598 shares of common stock held by VHCP-III and (iv) 228,644 shares of common stock held by VHCP-III Co-Invest.

Item 5. Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person

 

Not Applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not Applicable

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable

 

Item 9. Notice of Dissolution of a Group

 

Not Applicable

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

CUSIP No. 210373106

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

 

Dated: February 14, 2020

 

Venrock Associates V, L.P.				Venrock Management V, LLC
By:		Venrock Management V, LLC,		By:	/s/ David Stepp
		its General Partner			Authorized Signatory
By:		/s/ David Stepp
		Authorized Signatory
Venrock Partners V, L.P.				Venrock Partners Management V, LLC
By:		Venrock Partners Management V, LLC,		By:	/s/ David Stepp
		its General Partner			Authorized Signatory
By:		/s/ David Stepp
		Authorized Signatory
Venrock Entrepreneurs Fund V, L.P.				VEF Management V, LLC
By:		VEF Management V, LLC,		By:	/s/ David Stepp
		its General Partner			Authorized Signatory
By:		/s/ David Stepp
		Authorized Signatory
Venrock Healthcare Capital Partners II, L.P.				VHCP Management II, LLC
By:		VHCP Management II, LLC,		By:	/s/ David Stepp
		its General Partner			Authorized Signatory
By:		/s/ David Stepp
		Authorized Signatory
VHCP Co-Investment Holdings II, LLC				Venrock Healthcare Capital Partners III, L.P.
By:		VHCP Management II, LLC,		By:	VHCP Management III, LLC,
		its Manager			its General Partner
By:		/s/ David Stepp		By:	/s/ David Stepp
		Authorized Signatory			Authorized Signatory

 

 

CUSIP No. 210373106
VHCP Management III, LLC				VHCP Co-Investment Holdings III, LLC
By:		/s/ David Stepp		By:	VHCP Management III, LLC,
		Authorized Signatory			its Manager
				By:	/s/ David Stepp
					Authorized Signatory
Bong Koh				Nimish Shah
By:		/s/ David Stepp		By:	/s/ David Stepp
		David Stepp, as attorney-in-fact			David Stepp, as attorney-in-fact

 

EXHIBITS

 

A: Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G/A filed with the Securities and Exchange Commission on October 9, 2019)

B: Power of Attorney for Bong Koh (incorporated by reference to Exhibit B to the Schedule 13G/A filed with the Securities and Exchange Commission on October 9, 2019)

C: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit C to the Schedule 13G/A filed with the Securities and Exchange Commission on October 9, 2019)